Who was studied, and how
Three numbers in the abstract
Where each one falls
Where it lands on the map
188people in the Effectiveness of the Combination Liraglutide and Metformin on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With Polycystic Ovarian Syndrome, Obesity and Infertility trial, from 2023
of them with obesity, in this paper
The trial randomly assignedassigned by chance
GLP-1 receptor agonists
metformin
Probably lowered insulin sensitivity−0.40
Probably lowered body mass index−1.02
No clear effect on abdominal girth−0.45
randomisedthe abstract, start to end
… (standard mean difference [SMD] -0.40, 95% confidence interval [CI] -0.74 to -0.06, P = 0.02) and reducing body mass index (SMD -1.02, 95% CI -1.85 to -0.19, P = 0.02) and abdominal girth (SMD -0.45, 95% CI -0.89 to -0.00, …
← favours treatmentfavours comparator →
could be chanceInsulin sensitivityGLP-1 receptor agonists vs metformin
−0.40−0.74 to −0.06
Body mass indexGLP-1 receptor agonists vs metformin
−1.02−1.85 to −0.19
Abdominal girthGLP-1 receptor agonists vs metformin
−0.45−0.89 to 0.00
GLP-1 receptor agonistsGlycemic controlBody weight & composition
1 / 4